Beyond the Pill: Remepy and Merck KGaA Forge Alliance to Pioneer 'Hybrid Drugs'

NEW YORK, NY – April 28, 2026 – A landmark collaboration announced today between digital therapeutics pioneer Remepy and global science and technology company Merck KGaA, Darmstadt Germany, is set to explore a new frontier in medicine. The partnership will focus on developing "Hybrid Drugs," an emerging class of therapy that combines traditional pharmaceuticals with personalized, AI-driven software applications, with an initial focus on treating rare tumors in the United States.

This alliance represents a significant validation for the burgeoning field of integrated therapeutics, signaling that major pharmaceutical players are now making strategic investments into solutions that go beyond the pill. By pairing a drug with a digital counterpart in a single prescription, the two companies aim to create more effective, holistic treatments that can improve patient outcomes by addressing both the biological and behavioral aspects of a disease.

The Dawn of Hybrid Drugs

At the heart of the collaboration is the concept of the Hybrid Drug, a novel therapeutic category that fundamentally rethinks how treatment is delivered. Unlike standalone digital therapeutics (DTx), which are prescribed separately from medication, a Hybrid Drug integrates a pharmacological agent with a digital therapeutic protocol into a single, cohesive product. Patients receive a prescription that includes both the physical medication and access to a sophisticated mobile application designed to work in concert with it.

Remepy, the New York-based pioneer in this space, develops what it calls "Digital Molecules™." These are evidence-based motor, cognitive, and behavioral interventions delivered through an app. The software uses artificial intelligence to deliver personalized, adaptive protocols that can include exercises based on sensory integration, cognitive behavioral therapy, and mindfulness. The goal is to trigger physiological effects through the brain - enhancing neuroplasticity, modulating the immune system, and optimizing the body's response to the accompanying drug.

"Remepy's Hybrid Drug platform combines traditional drugs with evidence-based AI enabled digital interventions delivering personalized, adaptive integrative treatment," said Dr. Michal Tsur, Co-founder and Co-CEO at Remepy, in a statement. "The new advances in regulatory frameworks, supporting the integration of software with drugs, enable the pharma industry to use the power of the digital world to differentiate drugs, enhance their efficacy and amplify their label."

Early research conducted by Remepy has shown promising results. The company has completed controlled studies that reportedly demonstrated significant improvements in brain connectivity, reductions in pro-inflammatory biomarkers, and enhanced psychological and cognitive measures in subjects using their app-based interventions. One of its leading candidates, Hybridopa for Parkinson's Disease, recently met its primary endpoint in a double-blind, placebo-controlled study and is slated to begin Phase 3 testing later this year.

A Strategic Bet for Big Pharma

For Merck KGaA, Darmstadt Germany, this collaboration is more than just an exploratory venture; it is a calculated strategic move that aligns with its broader vision for the future of healthcare. The company has been actively integrating digital solutions across its business, focusing on patient-centric approaches and leveraging AI to accelerate research and development. This partnership marks its first major foray into combining drugs with app-based therapeutics for rare oncology, a field with significant unmet needs.

The strategic value for a pharmaceutical giant is multifaceted. In an increasingly competitive market, Hybrid Drugs offer a powerful way to differentiate a product. By demonstrating that a drug-software combination leads to superior clinical outcomes compared to the drug alone, a company can create a compelling value proposition for doctors, patients, and payers. This approach can enhance a drug's efficacy, potentially expand its approved uses, and build a protective moat around a product that is harder for competitors to replicate.

Furthermore, the collaboration's initial focus on a rare tumor area is telling. Patients with rare diseases often face fragmented care and a lack of specialized support. An integrated digital tool can provide crucial, continuous support, help manage complex symptoms, and gather valuable real-world data that can inform future treatment adjustments and research, making it an ideal testing ground for this new therapeutic model.

Navigating a New Regulatory Frontier

This new wave of medical innovation is made possible by an evolving regulatory landscape, particularly in the United States. The U.S. Food and Drug Administration (FDA) has been developing clearer pathways for drug-software combinations, most notably through its draft guidance on Prescription Drug Use-Related Software (PDURS).

The PDURS framework clarifies how software intended to be used with a specific prescription drug will be regulated. It defines the output from such software - whether it's a reminder, a piece of educational content, or data tracking - as a form of drug "labeling." While some industry stakeholders have raised concerns about the potential for excessive regulatory burden, the guidance provides a much-needed roadmap for companies like Remepy and Merck KGaA.

Under this evolving framework, there appear to be two primary routes to market for a Hybrid Drug. The first is to seek approval for the drug-software pair as a single, new combination product, which is the path Remepy is pursuing for its Parkinson's therapy. The second option involves using the PDURS pathway to secure a label expansion for an existing drug, proving that the addition of the software component provides a clinical benefit and justifies its inclusion in the drug's official labeling. This dual-pathway system offers flexibility and opens the door for both new and existing drugs to be enhanced with digital technology.

Reshaping the Economics of Digital Health

Perhaps one of the most significant implications of the Hybrid Drug model is its potential to solve the economic puzzle that has long challenged the digital therapeutics industry. While many standalone DTx products have demonstrated clinical value, they have often struggled to secure consistent reimbursement from insurers, hindering widespread adoption.

By bundling the digital component with a traditional pharmaceutical, the Hybrid Drug model shifts digital health innovation into the established and well-understood economics of the pharmaceutical industry. The software is no longer a separate product seeking reimbursement but an integral part of a single prescribed therapy that flows through existing channels for drug development, commercialization, and payment. This integration could unlock a more sustainable business model for digital health innovation.

The financial terms of the deal, estimated to be in the tens of millions of dollars including an upfront payment, development support, and potential royalties for Remepy, underscore the tangible value being placed on this integrated approach. For Remepy, which has raised $26 million in funding to date, the partnership provides not only capital but also the immense resources and market access of a global pharmaceutical leader. For the healthcare system, it promises a future where technology and biology are no longer separate domains but are seamlessly woven together to deliver more personalized and effective care to the patients who need it most.

---

Editorial Note: This article has been updated to reflect the correct total funding raised by Remepy to date, which is $26 million, rather than the previously stated $15 million. We have also included an illustration of the "Hybrid Drug" concept and a portrait of the founders provided by the company.